STEP-CRISPR
Proof-of-concept for neurological gene editing
Key Facts
About Couragene
Couragene is a private, pre-clinical stage biotech developing a proprietary chemical engineering platform called STEP (Stimuli-responsive Traceless Engineering Platform) for the delivery of genetic medicines. The platform aims to address key limitations of current delivery vehicles like viral vectors and lipid nanoparticles, particularly for brain-targeted therapies, by creating small, cell-penetrating constructs that release their functional payload intracellularly. Early proof-of-concept data demonstrates the platform's ability to enable brain-wide gene editing in mice using a CRISPR-Cas9 construct. The company is led by a team with expertise in drug delivery, gene therapy, and clinical development.
View full company profile